- Home
- PETS vs RFL Comparison
PETS vs RFL Comparison
Compare PETS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PETS | RFL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Real Estate |
| Sector | Consumer Staples | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 61.1M |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PETS | RFL |
|---|---|---|
| Price | $2.58 | $1.47 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 135.6K | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.57 | $1.12 |
| 52 Week High | $4.32 | $3.19 |
Technical Indicators
Market Signals| Indicator | PETS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 31.15 | 72.54 |
| Support Level | $2.44 | $1.41 |
| Resistance Level | $2.93 | $1.64 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 8.93 | 75.00 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.